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Background:  Several  biohumoral  variables,  taken  individually,  are  predictors  of prognosis  in  patients  with
chronic  coronary  artery  disease  (CAD).  We  hypothesized  that  taken  together,  laboratory  tests  provide
prognostic  information  that  is  additive  to a complete  diagnostic  work-up.
Methods:  We  prospectively  examined  2370  consecutive  patients  with  chronic  CAD, as  shown  by a >50%
coronary  stenosis  (in  95%  of patients),  previous  coronary  revascularization  (in  31%  of patients),  and/or
previous  myocardial  infarction  (MI,  in 54%  of  patients).  We  tested  the  ability  of  laboratory  and  clinical
variables  to predict  future  cardiac  events  (cardiac  death  and  non-fatal  MI).
Results: During  follow-up  (median,  46  months),  147  patients  (6.2%)  died  from  cardiac  causes  and  81  (3.4%)
experienced  a non-fatal  MI. Using  multivariate  analysis,  after  adjustment  for  clinical  variables  (including
left  ventricular  ejection  fraction  and  angiographic  extent  of coronary  stenoses),  a high-density  lipopro-
tein  cholesterol  (HDLc)  concentration  <  35  mg/dL  (p  <  0.0001),  a neutrophil-to-lymphocyte  ratio  >2.4
(p  =  0.0014),  and an  fT3  serum  level  <  2.1  pg/mL  with  normal  thyrotropin  (low-T3  syndrome)  (p  = 0.0260)
showed  an  independent  and  incremental  prognostic  value,  and  were  associated  with  an  increase  in  the
rate  of  cardiac  events  of 86%,  57%  and  41%,  respectively.  When  these  variables  were  added  to clinical
and  instrumental  variables,  the  prognostic  power  of  the  model  increased  signiﬁcantly  (global  chi-square
improvement:  from  157.01  to 185.07,  p < 0.0001).
Conclusion:  Low  HDLc,  high  neutrophil-to-lymphocyte  ratio  and low-T3  syndrome,  both  individually
and  taken  together,  provide  prognostic  information  that  is independent  of  and  incremental  to the  main
clinical  and  instrumental  ﬁndings.
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In the management of patients with chronic CAD, laboratory
ests are performed very frequently in order to identify biohu-
oral cardiovascular risk factors, to monitor their trends, to assess
he effectiveness and safety of therapy, and preliminary to inva-
ive investigations and contrast media administration [1].  Various
tudies have examined the effect of individual biohumoral vari-
bles on the prognosis of patients with chronic CAD. We  tested the
ypothesis that laboratory tests, taken together, provide additional
rognostic information in patients with chronic CAD, and that this
nformation is independent of and incremental to commonly ana-
yzed clinical and instrumental variables.
∗ Corresponding author at: Fondazione Toscana G Monasterio, Via Moruzzi, 1
6124 Pisa, Italy. Tel.: +39 050 315 3396; fax: +39 050 315 2166.
E-mail address: francesco.sbrana@ftgm.it (F. Sbrana).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.09.005anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
Methods
Patients
Of 8522 patients admitted to the Cardiology Unit of our Insti-
tute between 2001 and 2007, we  prospectively studied a group of
consecutive patients at their ﬁrst hospital admission for chronic
CAD. Inclusion criteria were: (a) history of stable angina or the evi-
dence of inducible myocardial ischemia associated with coronary
stenoses that reduced the lumen of one or more coronary arteries by
>50%, (b) previous coronary artery bypass graft surgery, (c) previous
percutaneous coronary intervention, and/or (d) the documentation
of a previous myocardial infarction (MI) by clinical records. Out of
2871 patients initially screened, we  excluded 373 patients for a
clinical course compatible with an acute MI,  36 patients in whom
the ﬁnal diagnosis was  cardiomyopathy or myocarditis, 33 patients
for associated valvular heart disease of at least moderate entity, 10
patients for chronic renal failure under hemodialysis treatment and
vier Ltd. All rights reserved.
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Table  1
Clinical characteristics of patients.
Patient characteristics Overall
n = 2370
With events
n = 228
Without events
n  = 2142
p-Value
Age, mean (SD), years 67 (10) 70 (9) 67 (10) <0.0001
Male,  n (%) 1865 (79) 183 (80) 1682 (79) 0.542
Family history of premature CAD, n (%) 1144 (48) 103 (45) 1041 (49) 0.325
Diabetes mellitus, n (%) 628 (26) 86 (38) 542 (25) <0.0001
Hypertension, n (%) 1435 (60) 138 (61) 1297 (61) 0.994
Hypercholesterolemia, n (%) 1663 (70) 140 (61) 1523 (71) 0.0023
Obesity, n (%) 663 (28) 55 (24) 608 (28) 0.172
Smoker  in the last year, n (%) 1165 (49) 104 (46) 1061 (50) 0.260
Previous myocardial infarction, n (%) 1269 (54) 147 (64) 1122 (52) 0.0005
Exertional angina, n (%) 627 (26) 45 (20) 582 (27) 0.0176
Angina at rest, n (%) 438 (19) 41 (18) 397 (19) 0.8584
Mixed angina, n (%) 689 (29) 71 (31) 618 (29) 0.4901
Previous coronary artery bypass surgery, n (%) 284 (12) 52 (23) 232 (11) <0.0001
Previous percutaneous coronary interventions, n (%) 456 (19) 47 (21) 409 (19) 0.580
Left  ventricular ejection fraction, mean (SD), % 52 (11) 44 (14) 52 (11) <0.0001
Disease of one coronary vessel, n (%) 841 (36) 48 (21) 793 (37) <0.0001
Disease of two coronary vessels, n (%) 602 (25) 72 (32) 530 (25) 0.0253
Disease of three coronary vessels, n (%) 404 (17) 58 (25) 346 (16) 0.0005
Disease of the left main stem, n (%) 234 (10) 36 (16) 198 (9) 0.0025
Disease of secondary vessels only, n (%) 175 (7) 9 (4) 166 (8) 0.0443
Non-signiﬁcant stenosis, n (%) 114 (5) 5 (2) 109 (5) 0.0706
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old values have been utilized to indicate statistically signiﬁcant variables.
 patients for overt hyperthyroidism. During hospitalization, each
atient had undergone a diagnostic work-up that included labo-
atory testing, two-dimensional echocardiography, and coronary
ngiography. The characteristics of the 2370 patients studied are
llustrated in Table 1.
The criteria used to deﬁne diabetes mellitus, arterial hyper-
ension, hypercholesterolemia and obesity were consistent with
nternational guidelines [2–4]. The left ventricular (LV) ejection
raction was measured by two-dimensional echocardiography
sing the single-plane or the biplane Simpson’s rule. After read-
ng the coronary arteriography, each patient was  assigned an
ngiographic score whereby 1 = single vessel disease, 2 = two-vessel
isease, 3 = three-vessel disease, 4 = disease of left main stem, 0.5
isease of secondary vessels only, and 0 = absence of signiﬁcant
oronary stenoses [5].  The LV ejection fraction was <35% in 13%
f patients, and ranged between 35 and 50% in 24% of patients. A
ulti-vessel coronary artery disease or a stenosis of the left main
tem were present in 52% of patients.
aboratory tests
The ﬁrst day of hospital admission, samples of peripheral venous
lood were drawn from the antecubital vein after patient overnight
asting, and processed for a complete series of routine laboratory
ssays. The laboratory variables explored were hematocrit, white
lood cell (WBC) count, neutrophil-to-lymphocyte (N/L) ratio,
latelet count, fasting glucose, serum creatinine, total cholesterol,
igh-density lipoprotein cholesterol (HDLc), triglycerides, TSH, fT3,
T4, and C-reactive protein. Low-density lipoprotein cholesterol
LDLc) concentration was calculated using the Friedewald equation
6]. The glomerular ﬁltration rate (eGFR) was estimated according
o the Cockcroft–Gault formula [7].  All laboratory tests were ana-
yzed as categorical variables based on the normal values of our
aboratory or previous studies. Although in current guidelines the
ut-off value for low HDLc is 40 mg/dL [8],  we considered a cut-
ff value of 35 mg/dL [9] because HDLc concentrations below this
hreshold were more strictly associated with cardiac events in our
atient population. The cut-off value of serum creatinine was  set to
.4 mg/dL [10,11].  The cut-off value of eGFR was set to 30 mL/min.
ow T3 syndrome was deﬁned as fT3 serum level < 2.1 pg/mL with-
ut accompanying TSH increase, hypothyroidism was  deﬁned asTSH > 3.8 IU/mL [12]. An N/L ratio of 2.42 was chosen on the basis
of previous studies from the same institution [13].
Follow-up
The entire group of patients was followed for up to 7 years
(median, 46 months). Patients were followed-up by periodic exam-
inations in the outpatient setting. In patients who  did not attend
this program, follow-up data were obtained using a written tele-
phone interview (administered to the patient or the patient’s family
by dedicated personnel) or mail questionnaires. In case of nega-
tive answers, the local demographic registry was queried. Cardiac
death was deﬁned as death caused by acute MI, death caused by
heart failure, or sudden and unexpected death not related to any
possible cause. The diagnosis of non-fatal MI  was  documented
by clinical records. The study protocol was approved by the local
committee on human research. In addition, patients gave written
informed consent to have their clinical data prospectively collected
for research purposes.
Statistical analysis
Continuous variables were expressed as mean and SD, cate-
gorical variables as percentages. The primary endpoint was the
occurrence of cardiac events, deﬁned as cardiac death or non-fatal
MI.  Predictors of survival were identiﬁed using univariate and mul-
tivariate analysis, performed using the Cox proportional hazards
regression model. Categorical variables were included in the model
as dummy  variables. Only those variables resulting signiﬁcant at
univariate analysis were entered into the regression model; the
signiﬁcant variables at multivariate analysis were selected using
a backward elimination procedure. Analysis was  initially limited
to the clinical and instrumental variables. Thereafter, laboratory
variables were examined, both before and after adjustment for
the independent clinical and instrumental predictors of survival,
as well as for medical treatment and myocardial revascularization.
The incremental prognostic information obtained after including
laboratory variables was evaluated by the chi-square. All statistical
tests were two-tailed; a p-value < 0.05 was considered signiﬁcant.
Statistical analysis was performed with the software program JMP
9 [SAS Institute Inc.] and R: A Programming Environment for Data
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Table  2
Laboratory variables.
Variable Overall
n = 2370
With events
n = 228
Without events
n = 2142
p-Value
Htc, mean (SD), (%) 41.1 (4.7) 40.2 (5.3) 41.2 (4.6) 0.0036
WBC/mm3, mean (SD) 7.5 (2.2) 7.7 (2.2) 7.4 (2.2) 0.0993
Neutrophil/lymphocyte ratio, mean (SD) 2.6 (2.2) 3.3 (3.0) 2.6 (2.1) <0.0001
PLT/mm3, mean (SD) 226.6 (67.2) 224.4 (69.4) 226.8 (67.0) 0.6059
Glucose, mean (SD), (mg/dL) 107.7 (36.6) 111.4 (38.0) 107.4 (36.4) 0.1171
Creatinine, mean (SD), (mg/dL) 1.1 (0.3) 1.2 (0.4) 1.0 (0.3) <0.0001
Total  cholesterol, mean (SD), (mg/dL) 184.8 (42.9) 180.2 (43.0) 185.2 (42.8) 0.0948
HDL  cholesterol, mean (SD), (mg/dL) 40.4 (11.1) 39.8 (12.9) 40.4 (10.9) 0.3790
LDL  cholesterol, mean (SD), (mg/dL) 119.2 (36.9) 116.3 (34.6) 119.5 (37.1) 0.2130
Triglycerides, mean (SD), (mg/dL) 129.7 (77.4) 124.5 (59.3) 130.2 (79.0) 0.3185
Low  T3 syndrome, n (%) 585 (26) 79 (34.6) 506 (23.6) 0.0003
Hypothyroidism, n (%) 205 (9) 179 (78.5) 26 (1.2) <0.0001
C-reactive protein, mean (SD), (mg/dL) 1.0 (2.8) 1.1 (2.8) 0.9 (2.8) 0.4718
Htc, hematocrit; WBC, white blood cells; PLT, platelet count; HDL, high-density lipoprote
Bold  values have been utilized to indicate statistically signiﬁcant variables.
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omputing].
esults
During follow-up (median, 46 months), 277 of the 2370 patients
ied, 147 of whom from cardiac causes, and 81 experienced a
on-fatal MI.  The 7-year rate of cardiac events (cardiac death
nd non-fatal MI)  was 19.8%. A plot of cardiac event-free sur-
ival in the whole population is shown in Fig. 1. Patients with
ardiac events were older, more frequently diabetic, and more
able 3
aboratory predictors of cardiac event-free survival using univariate analysis, both before
Variable Not adjusted 
HR 95% CI 
Htc < 36% if male, <40% if female 1.71 1.31–2.24 
WBC  > 11.900 mm−3 1.45 0.75–2.54 
Neutrophils/lymphocytes > 2.4 1.76 1.36–2.30 
PLT  > 410 mm−3 1.20 0.43–2.62 
Glucose > 110 mg/dL 1.42 1.09–1.86 
Creatinine > 1.4 mg/dL 2.88 2.11–3.88 
Total  cholesterol > 200 mg/dL 0.89 0.67–1.18 
HDL  cholesterol < 35 mg/dL 1.87 1.43–2.44 
LDL  cholesterol > 100 mg/dL 0.94 0.71–1.25 
Triglycerides > 150 mg/dL 1.06 0.79–1.41 
Low  T3 syndrome 1.74 1.30–2.33 
Hypothyroidism 1.83 1.17–2.76 
C-reactive protein > 0.4 mg/dL 1.38 1.05–1.81 
R, hazard ratio; CI, conﬁdence interval; Htc, hematocrit; WBC, white blood cells; PLT, pl
old  values have been utilized to indicate statistically signiﬁcant variables.in; LDL, low-density lipoprotein.
frequently had a previous MI  or previous coronary artery bypass
graft surgery than patients without events. Furthermore, patients
with events had lower LV ejection fraction and more severe coro-
nary atherosclerosis than those without events during follow-up
(Table 1). At Multivariate Cox regression analysis, the following
clinical and instrumental variables were signiﬁcant independent
predictors of event-free survival: age (HR 1.04, 95% conﬁdence
interval [CI]: 1.02–1.05, p < 0.0001), diabetes mellitus (HR 1.39,
95%CI: 1.06–1.82, p 0.0194), LV ejection fraction (HR 0.96, 95%CI:
0.95–0.97, p < 0.0001) and the extent of coronary stenoses (HR 1.33,
95%CI: 1.19–1.50, p < 0.0001). A 1-year increase in age, the presence
of diabetes, a 1% increase in ejection fraction, and a 1-point increase
in coronary angiographic score were associated with a change in the
risk of cardiac events by 4%, 39%, −4% and 33%, respectively.
As shown in Table 2, patients with cardiac events during follow-
up had higher N/L ratio, higher creatinine levels, and presented
hypothyroidism or low T3 syndrome more frequently than did
those without events. Table 3 shows the laboratory predictors of
event-free survival at univariate analysis. After adjustment for the
clinical and instrumental variables, the signiﬁcant laboratory pre-
dictors of survival were low hematocrit, elevated N/L ratio, elevated
serum creatinine, low HDLc concentration and low T3 syndrome
(if considered separately). Using multivariate analysis, and after
adjustment for the clinical and instrumental variables, the lab-
oratory independent predictors of a worse survival were HDLc(Table 4, upper panel). A low HDLc, an elevated N/L ratio and a
low T3 syndrome were associated with an increase in the rate of
cardiac events of 86%, 57% and 41%, respectively. Plots of cardiac
 and after adjustment for the clinical and instrumental variables.
Adjusted for clinical and instrumental variables
p-Value HR 95% CI p-Value
0.0003 1.33 1.01–1.75 0.0409
0.2487 1.42 0.73–2.49 0.2823
<0.0001 1.68 1.29–2.19 0.0001
0.6928 1.25 0.44–2.72 0.6399
0.0101 1.05 0.78–1.42 0.7171
<0.0001 1.69 1.21–2.31 0.0022
0.4366 1.06 0.79–1.40 0.6632
<0.0001 1.95 1.48–2.57 <0.0001
0.6635 1.03 0.78–1.37 0.8421
0.6816 1.20 0.88–1.61 0.2394
0.0002 1.56 1.16–2.09 0.0032
0.0093 1.46 0.92–2.21 0.0988
0.0197 1.27 0.97–1.68 0.0791
atelet count; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table  4
Final independent laboratory predictors of cardiac event-free survival using multi-
variate analysis, after adjustment for the clinical and instrumental variables.
Variable Adjusted for clinical and instrumental
variables
HR 95% CI p-Value
HDL cholesterol < 35 mg/dL 1.86 1.40–2.46 <0.0001
Neutrophils/lymphocytes > 2.4 1.57 1.19–2.08 0.0014
Low  T3 syndrome 1.41 1.04–1.91 0.0260
HDL cholesterol < 35 mg/dL 1.80 1.34–2.40 <0.0001
Neutrophils/lymphocytes > 2.4 1.52 1.14–2.02 0.0039
Low  T3 syndrome 1.35 0.99–1.85 0.0570
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R, hazard ratio; CI, conﬁdence interval; HDL, high-density lipoprotein; eGFR, esti-
ated glomerular ﬁltration rate.
vent-free survival for patients with HDLc≥ or <35 mg/dL, with N/L
atio≤ or >2.42, or with or without low T3 syndrome are illustrated
n Fig. 2. When renal function was estimated by the eGFR, a value
f <30 mL/min became an independent predictor of cardiac event-
ree survival (Table 4, lower panel). Of note, low T3 syndrome lost
art of its statistical signiﬁcance.
Adding to the clinical and instrumental variables those extracted
rom laboratory tests, the prognostic information increased signif-
cantly. As a matter of fact, the global chi-square improved from
57.01 (clinical and instrumental variables) to 185.07 (+laboratory
ariables; p < 0.0001). Considering cardiac death as the only end-
oint, low HDLc, high N/L ratio and low T3 syndrome remained
ndependent predictors of survival. Considering non-fatal MI  as the
nly end-point, low HDLc concentration was the only laboratory
redictor of event-free survival. In a subgroup analysis, low T3 syn-
rome was not an independent predictor of event-free survival in
ig. 2. Plots of cardiac event-free survival for patients with HDLc≥ or <35 mg/dL
top panel), N/L ratio≤ or >2.42 (middle panel), or with or without low T3 syndrome
lower panel).ology 61 (2013) 132–137 135
females, in patients younger than age 65 years, and in those with
LV ejection fraction ≥40%.
Patients with and without cardiac events did not signiﬁcantly
differ as to beta-blockers, calcium antagonists, ACE inhibitors or
nitrate treatment, while they differed as to antiplatelet agents,
anticoagulant and lipid-lowering agents (Table 5). Patients with
and without events did not differ as to myocardial revasculari-
zation by coronary artery bypass graft surgery or percutaneous
coronary interventions (Table 5). In order to explore whether dif-
ferences in medical treatment could have affected the ability of
laboratory variables to predict patient outcome, the regression
model was  repeated after adjustment for the antiplatelet and
anticoagulants agents, lipid-lowering agent and coronary revas-
cularization procedures. Low HDLc (p = 0.0004), high N/L ratio
(0.0087) and eGFR < 30 mL/min remained independent predictors
of event-free survival, while low T3 syndrome lost its predictive
power (p = 0.1729).
Discussion
This study shows that routine laboratory tests, both individually
and taken together, provide independent and incremental informa-
tion on the prognosis of patients with chronic CAD. It is known that
alterations in lipid metabolism, renal function, thyroid homeosta-
sis and complete blood count – taken individually – can inﬂuence
the prognosis of CAD patients. This study shows that this informa-
tion is independent and additive with respect to clinical variables.
The ability to predict cardiovascular events is in fact maintained
even after adjusting for the main factors that emerge from a com-
prehensive diagnostic work-up, and after adjustment for medical
treatment and coronary revascularization.
Low HDL cholesterol
For many years our efforts in the prevention and treatment of
CAD have been primarily aimed at lowering LDLc [14]. However,
it has been known since the Framingham Study that cardiovascu-
lar risk is also inﬂuenced by HDLc [15], which facilitates reverse
cholesterol transport and exerts an antioxidant activity [16]. Thus,
an estimated 1 mg/dL higher HDLc is associated with a 2% lower risk
of CAD for men  and a 3% lower risk for women, while low levels of
HDLc are associated with a more unfavorable cardiovascular prog-
nosis [17]. In our patients with chronic CAD, LDLc did not appear
to exert any effect on the prognosis while low HDLc levels had a
negative prognostic impact. In the author’s opinion, the effects of
LDLc on survival are blunted in this study by the pharmacological
treatment – mainly statins – which reduces LDLc but has little effect
on HDLc.
How low HDLc must be in order to negatively affect patients’
outcome deserves some consideration. In our population HDLc con-
centrations < 40 mg/dL were found in 41% of patients, and were
not associated with prognosis after adjustment for clinical vari-
ables (p = 0.86). However, HDLc concentrations < 35 mg/dL, which
occurred in 32% of patients, affected the prognosis adversely, even
after adjustment for clinical variables (p < 0.0001). Therefore, it is
the very low levels of HDLc that must be regarded with particular
attention in order to risk-stratify CAD patients [18].
Finally, the results of this study underline, if needed, the pro-
gnostic impact of lipid-lowering drugs, which proved to be an
independent predictor of event-free survival.
Low T3 syndromeThe effects of abnormal thyroid metabolism on the cardiovascu-
lar system have been known for many years [19]. Speciﬁcally, low
T3 syndrome, characterized by reduced serum levels of total and
136 F. Sbrana et al. / Journal of Cardiology 61 (2013) 132–137
Table  5
Medical treatment and myocardial revascularization.
Variable Overalln = 2370 With eventsn = 228 Without eventsn = 2142 p-Value
Antiplatelet, n (%) 1976 (83) 170 (74) 1806 (84) 0.0002
Anticoagulants, n (%) 559 (24) 79 (34) 480 (22) <0.0001
Beta  blockers, n (%) 1449 (61) 129 (56) 1320 (61) 0.1373
Calcium antagonists, n (%) 332 (14) 35 (15) 297 (13) 0.5437
Angiotensin-converting enzyme inhibitors, n (%) 1042 (43) 99 (43) 943 (44) 0.8615
Nitrates, n (%) 1608 (67) 149 (65) 1459 (68) 0.3958
Lipid-lowering agents, n (%) 1762 (74) 144 (63) 1618 (75) <0.0001
Coronary artery bypass graft surgery, n (%) 517 (21) 52 (22) 465 (21) 0.7026
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of the patient, since the prognosis of CAD patients is only partlyPercutaneous coronary interventions, n (%) 1166 (49)
old values have been utilized to indicate statistically signiﬁcant variables.
ree T3 in the presence of serum TSH and fT4 within normal limits,
as proved to be a powerful determinant of prognosis in patients
ith chronic heart failure [12]. Increased mortality in low T3 syn-
rome has also been observed in patients with acute MI  [20]. More
ecently, an inverse correlation between fT3 levels and coronary
therosclerosis has been found in a series of patients with CAD in
he absence of previous MI  and LV dysfunction [21]. In this study
ore than half of the patients had a previous MI,  and over one-third
ad an LV ejection fraction of <50%. This study further conﬁrms the
egative prognostic impact of low T3 syndrome in an unselected
roup of patients with chronic CAD. In addition, a subgroup analysis
as shown that the negative prognostic impact of low T3 syndrome
s mainly present in male patients, in patients older than 65 years,
nd in those with LV ejection fraction < 40%. Very recently, low T3
as associated with exercise capacity, but only in patients with
evere functional impairment [22].
BC with differential
Previous studies have shown leukocytosis to be an independent
redictor of future cardiovascular events, both in healthy individ-
als and in patients with stable angina, unstable angina, or a history
f myocardial infarction [23]. In our population WBC  count did
ot show any predictive power, conﬁrming previous investigations
24]. Complete blood count differential deserves a different consid-
ration. Very recently, the usefulness of the N/L ratio (an emerging
arker of inﬂammation) in predicting short- and long-term mor-
ality has been shown in patients with non-ST-elevation myocardial
nfarction and in those with decompensated heart failure [25,26].
ur study extends to a larger patient population previous observa-
ions on the association between the N/L ratio and patient outcome
n chronic CAD [13]. Accordingly, relative lymphocyte count should
e incorporated into clinical decisionmaking models to facilitate
isk stratiﬁcation in CAD.
After adjustment for potential confounders, a low baseline
ematocrit has been shown to be a predictor of early and late mor-
ality in patients undergoing percutaneous coronary interventions
27], coronary artery bypass graft surgery [28], and in those with
cute MI  [29]. Finally, anemia proved to be an independent predic-
or of death and major adverse events among elderly patients with
table CAD [30], as conﬁrmed in our patient population. The fact
hat anemia was not an independent predictor of survival at mul-
ivariate analysis likely reﬂects the interference with other factors,
uch as kidney disease.
erum creatinine and eGFR
Cardiovascular mortality is 10–30 times higher in dialysis
atients than in the general population [31,32]. To avoid the well-
nown prognostic effects of chronic kidney disease, we excluded
atients who were on hemodialysis. However, even small increases
n serum creatinine are associated with a worse cardiovascular114 (50) 1052 (49) 0.7990
prognosis [33], as conﬁrmed in our cohort of patients. On a prac-
tical level, patients with even mild forms of renal failure must be
considered high cardiovascular risk patients, for whom we must
aim to achieve more ambitious therapeutic goals. Of note, serum
creatinine was not an independent predictor of survival at multi-
ple logistic regression, while the eGFR was. This observation further
underlines the advantages of estimating the glomerular ﬁltration
rate over a simple measurement of creatinine concentration in the
clinical setting.
C-reactive protein
In patients with acute coronary syndrome, plaque rupture
causes an increase in systemic indicators of inﬂammation, such as
C-reactive protein. In this setting, high levels of C-reactive protein
are predictors of a worse prognosis. However, C-reactive protein is
a relatively moderate predictor of coronary heart disease [34], also
because its value can be affected by concomitant therapies such as
acetyl salicylic acid, by exposure to cigarette smoke or by concomi-
tant renal insufﬁciency. Our data on patients with chronic CAD are
consistent with these data, since C-reactive protein lost its predic-
tive value after adjustment for clinical and laboratory variables.
Study limitations
Thanks to the interdisciplinary nature of our research insti-
tute, and in view of coronary angiography, we  performed assays of
thyroid hormones and TSH in every patient. These laboratory exam-
inations are not performed routinely in every center. Furthermore,
we did not analyze in every patient the levels of neurohormones
[35], which have been shown to be related with patient outcome,
nor the levels of new biomarkers [36]. In addition, laboratory
tests were performed at initial patient admission, and we have no
data regarding the changes in laboratory variables over time, nor
patients’ adherence to medical treatment. Finally, the use of medi-
cations in our patients does not perfectly match current guidelines,
but is similar to that of the REACH registry [37], which reﬂects the
current standard of care. Since the COURAGE trial was  published in
2007 [38], more intensive medical therapy has been conducted.
Conclusion
Routine laboratory tests are widely available, cheap, and easy
to interpret. In patients with chronic CAD, several of these tests
provide independent and incremental prognostic information that
cannot be replaced by even accurate clinical and instrumental
examination. The results of this study are in line with a holistic viewpredicted by the extent of coronary lesions and by LV dysfunction,
while the outcome is largely inﬂuenced by non-cardiac variables
such as age, diabetes mellitus, blood cell count, lipid metabolism,
thyroid metabolism and kidney function.
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